Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07074327 · ClinicalTrials.gov registry record · Phase 1

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

A Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated.

Active
Registry status
Phase 1
Development phase
74
Enrollment target
1
Study location

NCT07074327 is a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD) that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 74 participants, below the 777-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07074327, a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.

Conditions Studied

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

  • DRUG VX-407
  • DRUG LNG/EE
  • DRUG NGM/EE
  • DRUG NET/EE
  • DRUG DRSP/EE

Study Locations (1)

Kansas

  • Altasciences - Kansas City - Overland Park

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2025-07-11
Est. Completion 2026-07-04
Phase Phase 1

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07074327

The ClinicalTrials.gov registry entry for NCT07074327 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 777-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (90% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) appearing as the primary indexed condition, and to 5 interventions - of which VX-407 is the first listed.

NCT07074327 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT07074327 about?

NCT07074327 is a clinical study titled "Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants". The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 ...

What is the current status of trial NCT07074327?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2025-07-11. Estimated completion is 2026-07-04.

What conditions does trial NCT07074327 study?

This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD).

What interventions are being tested in trial NCT07074327?

The interventions under investigation include: VX-407 (DRUG), LNG/EE (DRUG), NGM/EE (DRUG), NET/EE (DRUG), DRSP/EE (DRUG).

Who is sponsoring clinical trial NCT07074327?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07074327 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

All registered trials for this condition

Kansas

All trials with a study site in Kansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.